Therapeutics
Recombinant antibody production uses genetic engineering to create antibodies in labs, avoiding animal immunization. Antibody genes are cloned into expression vectors, inserted into host cells, and purified for various applications.
| 4 min read
Grow large quantities of adherent cells in a compact space with a substantial increase in cell growth surface compared to traditional vessels of comparable cubic footprint
| 1 min read
Traditional testing techniques for residual host cell DNA and mycoplasma contaminants fall short of the stringent requirements set by regulatory bodies
| 5 min read
First available product to utilize AstreAdept, Astrea Bioseparations’ novel nanofiber-based membrane material
| 1 min read
Develop and establish workflows with more efficient use of resources
| 1 min read
New SamuxMP mass photometer dramatically improves the efficiency of adeno-associated-virus characterization
| 2 min read
Automated synthesis of gene fragments using the BioXp™ system enables overnight production of error-corrected, de novo synthetic genes of up to 7,200 base pairs in length
| 1 min read
Identifying adaptive signaling pathways for designing improved targeted therapies
| 1 min read
Novel media supports automated T-cell expansion to deliver scalable, cost-effective cell therapy treatments
| 2 min read
The frozen Leukopaks will enable long-distance shipping of leukapheresis products without the concern of reduced cell viability encountered with fresh Leukopaks
| 2 min read
